Kolltan Pharmaceuticals Joins Celldex Therapeutics

Celldex Therapeutics acquired Kolltan Pharmaceuticals on November 29, 2016.

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline includes antibodies, antibody-drug conjugates and other protein-based therapeutics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases.

Visit Celldex.com to learn more about us.